Cargando…
Transthyretin cardiac amyloidosis
Transthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of heart failure (HF) and mortality worldwide. Advances in non-invasive diagnosis, coupled with the development of effective treatments, have shifted ATTR-CA from a rare and untreatable disease to a relatively prevalent...
Autores principales: | Porcari, Aldostefano, Fontana, Marianna, Gillmore, Julian D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897687/ https://www.ncbi.nlm.nih.gov/pubmed/35929637 http://dx.doi.org/10.1093/cvr/cvac119 |
Ejemplares similares
-
RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis
por: Ioannou, Adam, et al.
Publicado: (2023) -
Editorial: Proceedings and predictions in cardiac amyloidosis: unsolved mysteries and challenges for the future
por: Porcari, Aldostefano, et al.
Publicado: (2023) -
Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy
por: Fontana, Marianna, et al.
Publicado: (2023) -
Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis
por: Chacko, Liza, et al.
Publicado: (2022) -
Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage
por: Law, Steven, et al.
Publicado: (2020)